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resulting in a very high anaerobic glycolytic rate. Despite the fact that 
squamous cell carcinomas have a higher 18FDG-uptake, in general 
regarded as a poor prognostic factor, adenocarcinomas had a higher 
metastatic potential and a worse DFS. Therefore, the prognostic 
potential of 18FDG-PET should be interpreted in relation to histology. 
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Purpose/Objective: Treatment policy of inoperable or irresectable 
NSCLC (inop/irresNSCLC) in our department is consistant from 1995 
and onwards and has been guided by results of several subsequent 
EORTC studies (08844,08912,08972). Cc RT to a dose of 66 Gy/24 fx 
/2,75 Gy/33 days was combined with daily administration of cisplatin 
6mg/m2 1-2 hours before RT (total planned dose 144 mg/ m²) in 
patients with inop or irres disease (ccRCT). Patients were restaged 
and a resection (S) was considered in case of downstaging and strong 
indication or evidence of residual tumor, if radical S by lobectomy 
seemed feasible. Results of ccRCT from 1995-2004 were analysed and 
reported before. The 5 yr overall survival (OS) was 15%, the 5 yr local 
control rate (LCR) was 46 %. PET-staging was gradually introduced in 
our clinic in 2004 and became a standard staging procedure end of 
2006. 
The aim of the present study is to analyse the influence of PET staging 
on treatment results, and to check if our treatment is still appropiate 
in PET staged pts with inop/irresNSCLC. 
Materials and Methods: From2005-2012 136 pts were treated with cc 
RCT or RT. Eligibility criteria: biopsy proven irres or inop NSCLC not 
eligible for stereotactic radiotherapy, clinical and radiological 
suspicion for malignancy, FeV1>1 l, DLCO≥40%, adequate renal, 
haematological and pulmonary function (FeV1≥30 %). Chemotherapy 
was given in 118 pts and consisted of cisplatin 6 mg/m² in 112 pts (in 
6 pts preceded and in one patient followed by 2 courses of standard 
dose platinum containing chemotherapy, SDPtCT). 6 pts received 2 
courses of SDPtCT before RT. Radiotherapy was given by a conformal 
technique in all pts, elective treatment was omitted. The dose was 
defined according to the ICRU50 report. Dose constraints: max dose to 
spinal cord: 50 Gy/2 Gy or equivalent dose, MLD ≤20%, V20 ≤ 40%, 
V35oes ≤65%, max heart dose 40Gy (whole heart) or 50 Gy to 2/3 of 
the heart. Surgery was performed in 11 pts. 
Results: Stage (TNM2007) I, II, III, VI:12,10,101 (74,3%), 4 pts (solitary 
brain metastasis), unknown 9 pts. PET staging: 124 pts. Histology in 
128 pts: scc: 42pts, adenoca: 17pts, large cell undifferentiated ca: 60 
pts, malignant ca nos: 9 pts. Result in pts without histological 
diagnosis was equal to result in other pts. OS: The 1,2 and 5yr 
actuarial OS was 86%, 59% and 31% respectively (resp), mean S 49 
months (m) (95 % CI 38-62 m), median 33m. The 1, 2 and 5 yr LCR was 
83%, 69% and 51%. Mean and median follow-up period was 20 and 15m 
resp., (1,7-88). Late toxicity gr 1,2, 3,4 was present in 3,1,7 and 2 pts 
resp. Two pts died of complications. 
Results of S: lobectomy 10x, bilobectomy 1x. R0:9x, R1:1x, 
irresectable 1x. 
  
Conclusions: Selection of pts with inop/irres NSCLC by staging with 
PET-CT scan before ccRCT consisting of low dose cisplatin 6 mg/ m² 
given cc with radiotherapy 66 Gy/24 fx/33 days leads to an impressive 
increase in 5 yr OS(15to 31%) with similar LC 46-51%). The results are 
comparable with results of combined modality treatment with full 
dose RCT but with less toxicity. 
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Purpose/Objective: To retrospectively assess treatment outcome, and 
toxicity after a moderately escalated hypofractionated radiotherapy 
delivered with Helical Tomotherapy (HT) in locally advanced stage III 
inoperable non-small cell lung cancer (NSCLC) combined with 
sequential or concurrent chemotherapy. 
Materials and Methods: Sixty-one eligible patients were treated with 
combined platinum-based chemotherapy associated with a moderately 
escalated hypofractionated radiation course delivered with HT. The 
treatment schedule consisted of 30 daily fractions ranging from 2.25 
to 2.28 Gy each up to a total dose of 67.5-68.4 Gy to the gross tumour 
volume considered as the primary site and clinically proven nodal 
regions, without elective nodal irradiation. Applying a/bratio of 10, 
the corresponding normalized total dose at 2 Gy per fraction (NTD2) 
was 68.9-70 Gy. Overall survival and local control were assessed as 
well as acute and late toxicity using National Cancer Institute 
Common Terminology Criteria and Adverse Events (CTCAE) version 
3.0. 
Results: No Grade≥ 4 acute and late toxicity was reported. Acute 
Grade 3 treatment-related pneumonitis was detected in 12% of 
patients. Two patients, both receiving the concurrent 
schedule,developed a Grade 3 acute esophagitis. The overall 
incidence of late Grade 3 lung toxicity was 7%. No patients 
experienced a Grade 3 late esophageal toxicity. After a median 
follow-up of 25 months (range, 6-40 months), 2-year local control and 
overall survival rates were 65% and 53% for all patients, 30% of whom 
were stage IIIB. The same features for patients who received 
concurrent chemoradiation were 72% and 56%, respectively.  
Conclusions: Our findings show that a moderately hypofractionated 
radiation course delivered with HT is a feasible treatment option for 
patients with inoperable locally advanced NSCLC receiving 
chemotherapy (sequentially or concurrently). Hypofractionated 
radiotherapy with a dedicated technique allows safely dose 
escalation, minimizing the effect of tumor repopulation that may 
occur with prolonged treatment time. 
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Purpose/Objective: Radiotherapy quality assurance (RTQA) is now a 
requirement of radiotherapy clinical trials since poor protocol 
compliance has been shown to impact on outcomes. We aim to 
determine the degree of variation in lung cancer target volume 
delineation using pre-accrual benchmark cases. 
Materials and Methods: The IDEAL-CRT trial which is investigating 
isotoxic dose escalation and acceleration in lung cancer chemo-
radiotherapy requires all prospective principal investigators to submit 
pre-accrual contouring benchmark cases. The cases are assessed for 
protocol compliance and if necessary clinicians are asked to resubmit 
their contours following amendment. We collected all of the 
benchmark cases that had been submitted by June 2012 by 
prospective trial centre principal investigators in DICOM format. Each 
exercise was analysed using a tumour management group (TMG) 
consensus contour and Dice coefficient (DC), Jaccard index (JI) and 
geographical miss index (GMI) was calculated for each individual 
structure. The data was pre-processed to ensure uniform structure 
nomenclature and then analysed using automated trial analysis tools 
built using MATLAB R2011a and CERR v.4.0. 
Results: Up until May 2012 11 clinicians had submitted a total of 21 
benchmark cases; 11 for contouring case 1 and 10 for contouring case 
2. In total approximately 160 individual structure contours were 
analysed. Structures analysed included GTV, CTV, PTV, spinal cord 
(SC), right lung (RL), left lung (LL), heart and oesophagus. All 
conformity indices showed varying levels of conformity in clinician 
contouring. For IDEAL-CRT case 1 the median JI for the SC was 0.40 
(Interquartile Range (IQR) 0.04), the heart 0.90 (IQR 0.05), the GTV 
0.65 (IQR 0.16) and the oesophagus 0.41 (IQR0.08). For IDEAL-CRT 
case 2 the median JI for the SC was 0.46 (IQR 0.06), the heart 0.87 
(IQR 0.04), the GTV 0.77 (IQR 0.07) and the oesophagus 0.48 (IQR 
0.07). 
Conclusions: Our results show that clinician target volume conformity 
varies significantly within the IDEAL-CRT trial. Our results also suggest 
that the degree of variation depends upon the target structures shape 
and complexity. Prospective individual case review for the first 1-3 
cases is standard for this trial.  
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Purpose/Objective: To determine role of single photon emission 
tomography (SPECT) with 99mTc-MIBI and computerized tomography 
(CT) in selection of patients with non small cell lung cancer (NSCLC) 
for radiation therapy. 
Materials and Methods: SPECT with 99mTc-MIBI was performed after 
conventional staging in 84 NSCLC patients. Acquisition was started 15 
min after i/v injection of 740 MBq of 99mTc-MIBI. SPECT images of the 
chest were acquired over 360° using the following parameters: a 64 -
64 word matrix, a 3° angular step, and 30 s/frame. Diagnostic results 
of SPECT and conventional CT staging were validated by histological 
examinations of operation material. Various diagnostic strategies were 
tested as a tools for noninvasive staging of NSCLC and subsequent 
guidance of radiotherapy strategy. 
Results: According to histological verification 35 of 84 evaluated 
patients had lymh node (LN) invasion by NSCLC. Sensitivity (Sen), 
specificity (Sp) and accuracy (Ac) of SPECT in diagnosis of LN invasion 
by NSCLC were as follows: 80%, 67%, 72%. Diagnostic accuracy of CT 
for detection of LN involvement was inferior to SPECT: Sen – 70%, Sp - 
63%, Ac - 66%.  
Only combination of SPECT and CT data offer important diagnostic 
solutions. If LN involvement was detected by at least one of these 
methods Sen reached 94% with corresponded Sp -52%, Ac – 70%. This 
strategy was 88% sensitive for diagnosis of N2 LN invasion. It means 
that patients with normal SPECT and CT are suitable for curative 
radiosurgery without additional invasive staging procedures. 
In patients without pneumonia or atelectasis and SPECT plus CT sings 
of LN invasion Sp reached 97%, N2 invasion was also detected with 
high Sp (88%). Patients from this group are candidates for palliative 
radiotherapy. 
Conclusions: 
1. NSCLC patients without signs of LN involvement on SPECT and CT 
are suitable for curative radiosurgery.  
2. Patients without pneumonia or atelectasis and signs of N2 LN 
invasion detected on SPECT and CT are candidates for palliative 
irradiation. 
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Purpose/Objective: Tumor tissue can be re-oxygenated by 
inactivating peroxidase/catalase in the tumor tissue through the 
application of H2O2. This H2O2 is then degraded to produce oxygen. In 
this way, low-LET radioresistant tumors can be transformed into 
radiosensitive ones. Recently, we have developed a new enzyme-
targeting bio-radiosensitization treatment utilizing H2O2 for 
intratumoral injection (KORTUC II), and confirmed the safety & 
effectiveness of the treatment mainly for patients with locally 
advanced neoplasms (Ogawa Y et al. Int J Oncol 34: 609-618, 2009, 
39: 553-560, 2011). Therefore, in the study, we applied KORTUC II for 
non-surgical treatment for patients with breast cancer of stages I or II 
(KORTUC-BCT). The purpose of the present study was to establish a 
non-surgical BCT utilizing KORTUC II radiosensitization treatment.  
Materials and Methods: A new bio-radiosensitizing agent containing 
0.5% H2O2 and 0.83% sodium hyaluronate (a CD44 ligand) has been 
developed for intra-tumoral injection. This new method, named 
KORTUC II, was approved by our local ethics committee for the 
treatment of breast cancer and metastatic lymph nodes. A total of 
early-stage breast cancer pts. (stage I, 17 pts; stage II, 31 pts) were 
enrolled in the KORTUC II trial after providing fully informed consent. 
Mean age of the pts. was 60.8 years. The agent was injected into 
breast tumor tissue twice a week under US guidance, just prior to 
each administration of radiotherapy (RT). Hypofraction RT was 
administered for the breast & axilla using a tangential fields approach 
and field-in-field method; the energy level was 4 MV and the total RT 
dose was 44 Gy administered as 2.75 Gy/fraction. An electron boost of 
3 Gy was added three times. 
Results: Treatment was well tolerated with minimal adverse effects in 
all 48 pts. A total of 44 pts achieved cCR according to PET-CT and 
dynamic MRI study, and the study has not been performed for the 
remaining 4 patients yet. No patients showed any significant 
complications (excluding mild dermatitis: Grade I, 29 pts; Grade II, 19 
pts), and cosmetic results were excellent/good for 41 pts (85.4%). 
Eighteen pts. under 75 years old with stage II breast cancer underwent 
induction chemotherapy prior to KORTUC II treatment, and 41 pts. 
with ER-positive tumors also received hormonal therapy following 
KORTUC II. The mean duration of follow-up as of the end of June 2012 
was 33.6 months, at which time all 48 pts. were alive without any 
distant metastases. Only 1 pt. had local recurrence, which was 
discovered after 34 months of follow-up. The local control rate was 
97.9%. 
Conclusions: Non-surgical KORTUC-BCT can be performed using 
KORTUC II, which has three major characteristics: image-guidance by 
US; enzyme-targeting of peroxidase/catalase; and targeting of breast 
cancer stem cells via the CD44 receptor. KORTUC-BCT offers great 
potential as a viable non-invasive replacement for surgical BCT. 
Because KORTUC II is effective & safe, it has great potential to 
become a viable non-invasive replacement for surgical procedures and 
a valuable bio-radiosensitization method for low LET (linear energy 
tranfer)-radioresistant neoplasms. 
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Purpose/Objective: The present study is specifically addressed to 
investigate the feasibility of salvage radiotherapy treatment involving 
the whole breast in patients with local relapse managed with a second 
